We are not surprised that nearly 100 testosterone lawsuits are now pending in the federal proceeding, as we expect a large litigation.
New York, New York (PRWEB) June 17, 2014
Nearly 100 testosterone lawsuits (http://www.testosteronelawsuitclaims.com/) have been filed in a new federal multidistrict litigation established in Illinois federal court for product liability claims that allege the use of prescription low testosterone therapies caused men to suffer heart attacks, strokes, blood clots and other serious cardiovascular events, Bernstein Liebhard LLP reports. According to a Docket Report issued by the U.S. Judicial Panel on Multidistrict Litigation (JPML) on June 16th, at least 98 testosterone treatment lawsuits are now pending in the U.S. District Court, Northern District of Illinois, where all federal claims have been consolidated for coordinated pretrial proceedings. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)
“Our Firm hears from alleged victims of testosterone heart side effects on a regular basis. We are not surprised that nearly 100 testosterone lawsuits are now pending in the federal proceeding, as we expect a large litigation,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is investigating testosterone treatment lawsuits on behalf of men who allegedly have suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism and other serious heart events due to their use of testosterone treatment therapies.
Testosterone Treatment Lawsuits
According to court documents, the federal testosterone litigation was established by the JPML on June 6, 2014, when 45 cases were transferred to the Northern District of Illinois. While the majority of testosterone treatment lawsuits filed thus far involve AndroGel, cases have also been filed against the manufacturers of other medications included in this class. In addition to alleging the use of low testosterone therapies caused patients to suffer serious heart events, plaintiffs claim that the manufacturers of these drugs engaged in aggressive marketing that prompted men to seek testosterone replacement for symptoms associated with aging, including fatigue and low libido. As such, the complaints assert that many men underwent testosterone therapy in the absence of a true medical need.
Court filings indicate that testosterone treatment lawsuits began mounting in U.S. courts in the wake of a January 2014 announcement by the U .S. Food & Drug Administration (FDA) that it was investigating cardiovascular risks potentially associated with low testosterone therapies. The FDA’s review was prompted by the publication of studies that indicated the use of testosterone replacement drugs may increase the risk that some men will suffer heart attacks, stroke, or cardiovascular death.
Men who suffered life-threatening heart events allegedly due to the use of low testosterone therapies may be eligible to file their own testosterone lawsuit. To learn more about the growing litigation involving testosterone replacement drugs, please visit Bernstein Liebhard LLP’s website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com